(MENAFN- Zex PR Wire) Michigan, US, 7th November 2024, ZEX PR WIRE , With the rise of GLP-1 medications, such as Wegovy and Ozempic, making waves in the weight loss industry, Doctors Medical ...

HM17321 addresses a key limitation in current GLP-1-based therapies, which often lead to muscle loss as a side effect of significant weight reduction. "HM17321 is the novel concept of obesity drug ...

Current GLP-1-based obesity medications are effective in achieving 15-20% weight loss, but up to 40% of this loss can come from muscle, accompanied by a reduction in basal metabolic rate and a ...

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.

We INFORM. We INSPIRE. We EMPOWER. Founded by serial entrepreneur Sonalie Figueiras in 2011, Green Queen is a multi-channel digital news platform and a trusted global impact media brand. Our ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...